[go: up one dir, main page]

MA43977A - Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave - Google Patents

Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Info

Publication number
MA43977A
MA43977A MA043977A MA43977A MA43977A MA 43977 A MA43977 A MA 43977A MA 043977 A MA043977 A MA 043977A MA 43977 A MA43977 A MA 43977A MA 43977 A MA43977 A MA 43977A
Authority
MA
Morocco
Prior art keywords
treatment
cancer patients
kidney failure
severe kidney
severe
Prior art date
Application number
MA043977A
Other languages
English (en)
Inventor
Kenichiro Yoshida
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59501005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA43977A publication Critical patent/MA43977A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043977A 2016-02-05 2017-02-03 Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave MA43977A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291799P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
MA43977A true MA43977A (fr) 2018-12-12

Family

ID=59501005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043977A MA43977A (fr) 2016-02-05 2017-02-03 Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Country Status (12)

Country Link
US (4) US10456399B2 (fr)
EP (1) EP3412295A4 (fr)
JP (4) JP6882205B2 (fr)
KR (2) KR102412690B1 (fr)
AU (1) AU2017215825B9 (fr)
MA (1) MA43977A (fr)
NZ (1) NZ745113A (fr)
RU (1) RU2727598C2 (fr)
TW (1) TWI791430B (fr)
UA (1) UA123403C2 (fr)
WO (1) WO2017135412A1 (fr)
ZA (1) ZA201805245B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882205B2 (ja) * 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
EP4027989A4 (fr) * 2019-09-11 2023-09-06 Inspirna, Inc. Méthodes de traitement du cancer
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
CN118879871B (zh) * 2024-09-27 2025-05-30 中国人民解放军总医院第三医学中心 一种肾癌预后标志物tymp及tymp抑制剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763529B1 (fr) 1995-03-29 2003-07-23 Taiho Pharmaceutical Company Limited Derives d'uracile, agents de potentialisation d'effet antitumoral et agent antitumoral renfermant ces derives
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
PT1849470T (pt) * 2005-01-26 2017-09-22 Taiho Pharmaceutical Co Ltd Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
HUE035347T2 (en) * 2011-08-16 2018-05-02 Taiho Pharmaceutical Co Ltd Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
NZ712584A (en) * 2013-03-27 2018-03-23 Taiho Pharmaceutical Co Ltd Antitumor agent including irinotecan hydrochloride hydrate
TWI595879B (zh) * 2013-05-17 2017-08-21 Taiho Pharmaceutical Co Ltd Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity
CN106333952A (zh) 2014-02-19 2017-01-18 齐鲁制药有限公司 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法
JP6882205B2 (ja) * 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法

Also Published As

Publication number Publication date
US20200030329A1 (en) 2020-01-30
NZ745113A (en) 2021-12-24
KR102298144B1 (ko) 2021-09-03
RU2018131573A3 (fr) 2020-03-05
EP3412295A4 (fr) 2019-09-25
KR102412690B1 (ko) 2022-06-23
ZA201805245B (en) 2019-10-30
TW201728328A (zh) 2017-08-16
US20240148730A1 (en) 2024-05-09
KR20180104744A (ko) 2018-09-21
EP3412295A1 (fr) 2018-12-12
US10960004B2 (en) 2021-03-30
US20210177850A1 (en) 2021-06-17
TWI791430B (zh) 2023-02-11
JPWO2017135412A1 (ja) 2018-12-06
RU2727598C2 (ru) 2020-07-22
AU2017215825B2 (en) 2020-09-10
US20180338976A1 (en) 2018-11-29
AU2017215825B9 (en) 2020-11-26
WO2017135412A1 (fr) 2017-08-10
AU2017215825A1 (en) 2018-08-23
JP2023065622A (ja) 2023-05-12
UA123403C2 (uk) 2021-03-31
JP2021113228A (ja) 2021-08-05
JP6882205B2 (ja) 2021-06-02
US10456399B2 (en) 2019-10-29
RU2018131573A (ru) 2020-03-05
KR20210111348A (ko) 2021-09-10
JP2025013684A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
EP3488001A4 (fr) Traitement du cancer
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
MA43374A (fr) Méthodes de traitement de tumeurs malignes
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
IL258521B1 (en) Combination therapy for the treatment of cancer
EP3448263A4 (fr) Traitement électrothérapeutique
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
PT3622953T (pt) Tratamento combinado do cancro
MA46361A (fr) Traitement du cancer de la prostate
MA71411A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3766497A4 (fr) Médicament pour le traitement de la toux
SI3773558T1 (sl) Kombinirano zdravljenje artritične bolezni
EP3463461A4 (fr) Procédés de traitement de la myasthénie grave généralisée réfractaire
MA52627A (fr) Traitement du cancer
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3862000A4 (fr) Médicament de traitement de la toux chronique
IL257764B (en) Methods for treatment of diseases
EP3454793A4 (fr) Bobines de traitement d'anévrisme
JOP20190056A1 (ar) طرق لعلاج إصابة كلى حادة
MA53903A (fr) Méthode de traitement de la myasthénie grave